Practice pattern for postoperative management of endometrial cancer in Japan: A survey of the Japanese Gynecologic Oncology Group

• Published in: Gynecologic oncology 2009-12, Vol.115 (3), p.456-459
• Main Authors: Watanabe, Yoh, Kitagawa, Ryo, Aoki, Daisuke, Takeuchi, Satoshi, Sagae, Satoru, Sakuragi, Noriaki, Yaegashi, Nobuo
• Format: Article
• Language: English
• Subjects: Adjuvant therapy; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Carboplatin - administration & dosage; Chemotherapy, Adjuvant; Endometrial cancer; Endometrial Neoplasms - drug therapy; Endometrial Neoplasms - pathology; Endometrial Neoplasms - surgery; Female; Hematology, Oncology and Palliative Medicine; Humans; Japan; Japanese Gynecologic Oncology Group; Neoplasm Staging; Obstetrics and Gynecology; Paclitaxel - administration & dosage; Postoperative Care - methods; Practice Patterns, Physicians; Survey
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2009.08.016

Abstract Objective To determine the current status of postoperative management of endometrial cancer in Japan by surveying members of the Japanese Gynecologic Oncology Group (JGOG). Method We conducted an original mail survey regarding the status of postoperative treatment including indication criteria, treatment procedures, and chemotherapeutic regimen among all 226 active member institutions of the JGOG. Results A total of 199 institutions (88.1%) responded to the survey. A total of 4063 patients with endometrial cancer were treated at the member institutions of the JGOG over a year. As adjuvant therapy, chemotherapy (79.9%) was significantly ( p < 0.01) preferred over radiotherapy (13.0%) or hormonal therapy (7.1%). Furthermore, more than 50% of respondent institutions performed adjuvant therapy when patients exhibited International Federation of Gynecology and Obstetrics (FIGO) stage IB/G3/positive lymph-vascular space invasion (LVSI)/endometrioid adenocarcinoma or FIGO IB/G3/non-endometrioid histology, and more than 90% institutions administered adjuvant therapy when patients exhibited FIGO IC/G3/positive LVSI/endometrioid adenocarcinoma or FIGO stage IC/G3/regardless of LVSI/non-endometrioid histology. A combination of paclitaxel and carboplatin was the most preferred first-line regimen for adjuvant chemotherapy followed by combination regimens consisting of anthracycline and platinum. Conclusion The present survey provides relevant information regarding the current status of adjuvant therapy in Japanese patients with endometrial cancer.